Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name ERBB2 D769Y
Gene Variant Detail

ERBB2 D769Y (gain of function)

Relevant Treatment Approaches HER inhibitor (Pan) HER2 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 D769Y malignant peripheral nerve sheath tumor predicted - sensitive HER2 Inhibitor Lapatinib Case Reports/Case Series Actionable In a clinical case study, Tykerb (lapatinib) treatment resulted in clinical improvements, partial tumor size reduction, and metabolic response in a patient with neurofibroma/schwannoma hybrid nerve sheath tumor harboring ERBB2 (HER2) D769Y (PMID: 32017710). 32017710
ERBB2 D769Y Advanced Solid Tumor sensitive HER inhibitor (Pan) Poziotinib Preclinical - Cell culture Actionable In a preclinical study, Poziotinib (HM781-36B) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). 31588020
ERBB2 D769Y Advanced Solid Tumor sensitive HER2 Inhibitor Ibrutinib Preclinical - Cell culture Actionable In a preclinical study, Imbruvica (ibrutinib) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). 31588020
ERBB2 D769Y gastroesophageal junction adenocarcinoma predicted - resistant HER2 Inhibitor Neratinib Case Reports/Case Series Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926). 29420467
ERBB2 D769Y Advanced Solid Tumor sensitive HER inhibitor (Pan) Dacomitinib Preclinical - Cell culture Actionable In a preclinical study, Vizimpro (dacomitinib) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). 31588020
ERBB2 D769Y Advanced Solid Tumor sensitive HER2 Inhibitor Tarloxotinib Preclinical - Cell culture Actionable In a preclinical study, Tarloxotinib (TRLX) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). 31588020
ERBB2 D769Y Advanced Solid Tumor conflicting HER2 Inhibitor Lapatinib Preclinical - Cell culture Actionable In a preclinical study, Tykerb (lapatinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). 29967253
ERBB2 D769Y Advanced Solid Tumor conflicting HER2 Inhibitor Lapatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing ERBB2 (HER2) D769Y were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). 31588020
ERBB2 D769Y breast cancer sensitive HER2 Inhibitor Neratinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769Y reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880). 23220880
ERBB2 D769Y Advanced Solid Tumor sensitive Nazartinib Preclinical - Cell culture Actionable In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). 31588020
ERBB2 D769Y Advanced Solid Tumor sensitive HER inhibitor (Pan) Afatinib Preclinical - Cell culture Actionable In a preclinical study, Gilotrif (afatinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). 29967253
ERBB2 D769Y Advanced Solid Tumor sensitive HER inhibitor (Pan) Afatinib Preclinical - Cell culture Actionable In a preclinical study, Gilotrif (afatinib) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). 31588020
ERBB2 D769Y Advanced Solid Tumor conflicting HER2 Inhibitor Sapitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing ERBB2 (HER2) D769Y were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020). 31588020
ERBB2 D769Y Advanced Solid Tumor conflicting HER2 Inhibitor Sapitinib Preclinical - Cell culture Actionable In a preclinical study, Sapitinib (AZD8931) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). 29967253
ERBB2 D769Y Advanced Solid Tumor sensitive Osimertinib Preclinical - Cell culture Actionable In a preclinical study, Tagrisso (osimertinib) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). 31588020
ERBB2 D769Y Advanced Solid Tumor sensitive Osimertinib Preclinical - Cell culture Actionable In a preclinical study, Tagrisso (osimertinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). 29967253
ERBB2 D769Y urinary bladder cancer predicted - resistant HER2 Inhibitor Neratinib Case Reports/Case Series Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with bladder cancer harboring both ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926). 29420467
ERBB2 D769Y Advanced Solid Tumor sensitive HER2 Inhibitor Neratinib Preclinical - Cell culture Actionable In a preclinical study, Nerlynx (neratinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 29967253). 29967253
ERBB2 D769Y breast cancer sensitive HER2 Inhibitor Lapatinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880). 23220880
ERBB2 D769Y Advanced Solid Tumor sensitive HER2 Inhibitor Pyrotinib Preclinical - Cell culture Actionable In a preclinical study, Pyrotinib inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). 31588020
ERBB2 D769Y breast cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). 23220880
ERBB2 D769Y Advanced Solid Tumor resistant Trastuzumab Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing ERBB2 (HER2) D769Y demonstrated resistance to Herceptin (trastuzumab) treatment in culture (PMID: 29967253). 29967253
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04172597 Phase II Poziotinib A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Recruiting USA 0
NCT02673398 Phase II Neratinib Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer Active, not recruiting USA 0